Tirzepatide (Zepbound, Mounjaro) is a dual GIP/GLP-1 receptor agonist that significantly reduces hunger and slows gastric emptying, making strategic meal planning essential
The PIONEER studies used similar main endpoints
Rybelsus is a once-daily oral tablet (3, 7, 14, or 25 mg) approved for type 2 diabetes, cardiovascular risk reduction, and obesity (obesity indication added December 2025)
Larger, more comprehensive studies are needed to confirm these initial findings
aOR 0.43 [95% CI 0.28, 0.64]) [25, 44]
A menudo, los pacientes con cncer que se someten a tratamientos de quimioterapia o radioterapia, sufren fatiga, llevan una nutricin deficiente y presentan dficit de carnitina